Prostate Cancer

This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.

Primary androgen deprivation therapy in men with localized prostate cancer appears to offer no survival benefit.

The investigational 17,20 lyase inhibitor orteronel failed to significantly extend overall survival in an international phase III study of patients with metastatic castration-resistant prostate cancer.

Although the activity of enzalutamide (XTANDI) is blunted in patients with metastatic castration-resistant prostate cancer who have been treated previously with abiraterone acetate (ZYTIGA), a meaningful number of these patients still experience a decline in PSA level with enzalutamide, according to a recent study.

Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.

A study from the UCLA Ronald Reagan Medical Center appears to once again prove that time is money. The study’s findings indicate that up to $15 million could be saved annually by referring patients who are candidates for robot-assisted radical prostatectomy to surgeons and surgical centers with optimal operating times.

Astellas Pharma Inc. and Medivation Inc. have submitted a supplemental new drug application to the FDA seeking approval of enzalutamide (XTANDI) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy.

A new generation of prostate cancer biomarkers promises to alter the way in which urologists make clinical management decisions.

The U.S. Preventive Services Task Force recommendation against routine prostate cancer screening has resulted in a decrease in the number of PSA-based screenings ordered by physicians, with the greatest decline seen among urologists, according to findings of recently published study that one leading prostate cancer expert says raises more questions than it answers.

Levels of bisphenol A in men’s urine could be a marker of prostate cancer, and male exposure to other environmental chemicals used in the manufacture of plastics appear to negatively impact time to pregnancy, two separate studies have found.

Learn more about MRI-guided biopsy with these videos.

Radical prostatectomy is associated with a substantial long-term reduction in mortality in men with localized cancer, especially in younger patients, according to newly published data from one of the few randomized trials to directly address the surgery-versus-surveillance issue.

Prostate cancer patients who undergo robot-assisted radical prostatectomy have fewer positive surgical margins and less need for additional cancer treatments such as hormone or radiation therapy than patients undergoing open surgery, an observational study from UCLA’s Jonsson Comprehensive Cancer Center has found.

Most prostate cancer experts aren’t ready to call the incorporation of MRI fusion into prostate biopsies the gold standard in prostate cancer imaging and diagnosis. But they envision a day when it will be.

In clinical practice, experts told Urology Times, men who may benefit from MR-guided prostate biopsy generally fall into one of four scenarios.

Drugs and devices in the pipeline from VIVUS, Auxilium Pharmaceuticals, OncoGenex Pharmaceuticals, Veloxis Pharmaceuticals, OPKO Health, and Oxthera AB.

The makers of the Decipher and ConfirmMDx prostate cancer tests have announced separate agreements that will expand insurance coverage for the two tests.

High-dose supplementation with both selenium and vitamin E increases the risk of high-grade prostate cancer, according to a recent multicenter study. This risk depends upon a man’s selenium status before taking the supplements.

The type of primary treatment received for prostate cancer-surgery or radiation therapy-is the strongest predictor of lesser-known complications such as the need for additional surgical procedures and development of secondary cancers, according to the authors of a recently published study from the University of Toronto.

The second-generation androgen receptor antagonist enzalutamide (XTANDI) significantly improved survival and delayed the time to chemotherapy in men with previously untreated metastatic castrate-resistant prostate cancer, according to a recent study.

Promotion of strategies for the repeal of the sustainable growth rate formula and preservation of access to appropriate PSA screening are among the AUA’s top legislative priorities for 2014, the association announced.

A 46-gene diagnostic test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostatectomy, a recently published study found.

In this article, I outline my patient discussion concerning prostate cancer screening, which includes defining what the PSA test is, why to screen or not to screen, the screening controversy, current guidelines, and decision aids.

Prostate cancer patients treated with androgen deprivation therapy experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life 2 years after treatment, a recent study found.

A genomic test capable of predicting the probability of developing metastatic prostate cancer outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy, researchers reported at the Genitourinary Cancers Symposium in San Francisco.